Lynnette Fernandez-Cuesta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2741804/publications.pdf

Version: 2024-02-01

43 papers	6,458 citations	218677 26 h-index	361022 35 g-index
47 all docs	47 docs citations	47 times ranked	9754 citing authors

#	Article	IF	Citations
1	Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in <scp>DNA</scp> methylation. International Journal of Cancer, 2022, 150, 1987-1997.	5.1	4
2	Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers. Lung Cancer, 2022, 167, 98-106.	2.0	6
3	Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 73-80.	2.8	11
4	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology, 2020, 15, 29-49.	1.1	106
5	New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Translational Lung Cancer Research, 2020, 9, 2233-2244.	2.8	58
6	A molecular map of lung neuroendocrine neoplasms. GigaScience, 2020, 9, .	6.4	17
7	Needlestack: an ultra-sensitive variant caller for multi-sample next generation sequencing data. NAR Genomics and Bioinformatics, 2020, 2, lqaa021.	3.2	5
8	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. Journal of Thoracic Oncology, 2020, 15, 1037-1053.	1.1	40
9	Integrative and comparative genomic analyses identify clinicallyÂrelevant pulmonary carcinoidÂgroups and unveil the supra-carcinoids. Nature Communications, 2019, 10, 3407.	12.8	132
10	Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities. Translational Lung Cancer Research, 2019, 8, S430-S434.	2.8	25
11	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine, 2019, 48, 191-202.	6.1	55
12	New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management. Journal of Thoracic Oncology, 2018, 13, 752-766.	1.1	102
13	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications, 2018, 9, 1048.	12.8	254
14	Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clinical Cancer Research, 2018, 24, 33-42.	7.0	164
15	Small-Cell Cancer of the Lung: Pathology and Genetics. , 2018, , 403-403.		0
16	Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. Lung Cancer, 2018, 124, 95-101.	2.0	29
17	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	5.5	739
18	BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% ofÂMalignant Peritoneal Mesotheliomas. Journal of Thoracic Oncology, 2017, 12, 724-733.	1.1	67

#	Article	IF	Citations
19	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. Journal of Investigative Dermatology, 2017, 137, 197-206.	0.7	78
20	Genomic architecture of lung cancers. Current Opinion in Oncology, 2016, 28, 52-57.	2.4	9
21	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. EBioMedicine, 2016, 10, 117-123.	6.1	153
22	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Research, 2016, 22, 4837-4847.	7.0	223
23	Abstract 122: Comparative analysis of small cell lung cancer and other pulmonary neuroendocrine tumors. , 2016, , .		6
24	Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget, 2016, 7, 5273-5288.	1.8	60
25	Abstract 3156: NGS-based screening for TP53 mutations in circulating cell-free DNA: A first step towards early detection of lung cancers. , 2016, , .		0
26	Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer. Clinical Cancer Research, 2015, 21, 1989-1994.	7.0	61
27	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	27.8	1,634
28	Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology, 2015, 16, 7.	8.8	44
29	Abstract 752: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas. , 2015, , .		0
30	Cell-Autonomous and Nonâ€“Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. Cancer Discovery, 2014, 4, 246-257.	9.4	93
31	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature Communications, 2014, 5, 3518.	12.8	239
32	CD74â€“NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	9.4	238
33	Abstract 1531: Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets. , 2014, , .		13
34	Abstract 1542: Comprehensive genome and transcriptome analyses on small cell lung cancer. , 2014, , .		0
35	Abstract 441: Functional characterization of recurrent CD74â€NRG1 fusions in lung adenocarcinoma. , 2014, , .		0
36	Abstract 956: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas. , 2014, , .		0

#	Article	IF	Citations
37	Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Research, 2012, 14, R70.	5.0	52
38	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
39	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	7.1	410
40	p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Letters, 2011, 300, 215-224.	7.2	25
41	Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Research and Treatment, 2011, 125, 35-42.	2.5	27
42	p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. International Journal of Cancer, 2011, 128, 1813-1821.	5.1	29
43	p53 regulates the transcription of its Î”133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene, 2010, 29, 2691-2700.	5.9	60